UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission File Number 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of the Company approved all the proposals brought before the annual
general meeting of shareholders held on August 18, 2025 (following a one-week adjournment from the original meeting date) (the “Meeting”), by the
respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company’s Report of Foreign Private
Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on June 17, 2025, and sent in connection with the Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (File Nos. 333-193788, 333-201443, 333-203856, 333-259215 and 333-286197) of the Company, and will be a part thereof from the date
on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
Date: August 18, 2025
|
|
EVOGENE LTD.
(Registrant)
By: /s/ Yaron Eldad
——————————————
Yaron Eldad
Chief Financial Officer
|
